Collaborating, innovating, and finding new ways together to improve outcomes
Partnership culture within the clinical research industry has often been overlooked as a component of a successful outsourcing strategy. However, culture can support, inform, and maintain strategies and operational decision-making.Read the whitepaper
In this webinar, Sanofi and ICON discuss how they created a shared partnership/alliance culture, which has evolved both the outsourcing strategy and operating model. Attendees will learn about the specific tools and methods used to develop and support the Sanofi / ICON partnership, including:
In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.Read the article
This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.Read the whitepaper
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.Watch the webinar
More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.Watch the webinar
Gain insights on what it takes to be a trusted partner to sponsors in the clinical development industry.
From patient-centricity to venture capital networks.
Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.
Collaborating with patient advocacy organisations for better clinical research
LEO Pharma annoucvces strategic partnership with ICON, saying the deal will enable it to scale up its clinical trial operations in a way that is both patient-centric and cost-effective, while also supporting its ambition to create one of the ‘most effective and efficient clinical portfolio execution organisations in the industry’.
For years, pharmaceutical and medical device development have occurred in silos.
A hallmark of high-performing partnerships is the establishment and maintenance of a governance model that aligns the interests of the sponsor and the CRO.
ICON is currently engaging with the Tufts CSDD - with input and in collaboration with ICON’s biopharmaceutical company Partners of Choice (PoC) - and invites input into a proposed new taxonomy and framework to redefine CRO sourcing model terminology.
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
The In Vitro Diagnostics Regulation (IVDR) will have a lasting impact on the entire in vitro diagnostics (IVD) lifecycle, from development through clinical investigations and regulatory approval.
The COVID-19 pandemic disrupted clinical trials across all indications. For trials that persevered, COVID-19 impacted patient enrollment, participation, and data collection.
An end-to-end solution is required to run a successful digital trial.